Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 5/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.70 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.70 |
| ▸ | HTR1A | P08908 | 3/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.70 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.70 |
| ▸ | DRD3 | P35462 | 3/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.70 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.70 |
| ▸ | HTR2B | P41595 | 2/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.70 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nylidrin SCHEMBL159150 | 0.82 | HIF1A (1.00) | ADRA1ACYP2D6ADRA2AHIF1ALMNA | |
| Nylidrin SCHEMBL3701975 | 0.82 | HIF1A (1.00) | ADRA1ACYP2D6ADRA2AHIF1ALMNA | |
| Nylidrin SCHEMBL15517085 | 0.82 | HIF1A (1.00) | ADRA1ACYP2D6ADRA2AHIF1ALMNA | |
| Nylidrin SCHEMBL364078 | 0.81 | ADRA1A (1.00) | ADRA1ACYP2D6ADRA2AHIF1ALMNA | |
| Nylidrin SCHEMBL15512520 | 0.80 | HIF1A (0.95) | ADRA1ACYP2D6ADRA2AHIF1ALMNA | |
| SCHEMBL17565768 | 0.80 | SLC6A2 (0.80) | ADRA1ACYP2D6ADRA2AHIF1ALMNA | |
| SCHEMBL10777564 | 0.72 | ADRA1A (0.59) | ADRA1ACYP2D6ADRA2AHIF1ALMNA | |
| SCHEMBL10526089 | 0.70 | ADRA1A (0.57) | ADRA1ACYP2D6ADRA2AHIF1ALMNA | |
| SCHEMBL10523532 | 0.70 | ADRA1A (0.57) | ADRA1ACYP2D6ADRA2AHIF1ALMNA | |
| Nylidrin SCHEMBL13724281 | 0.70 | ADRB2 (0.73) | ADRA1ACYP2D6ADRA2AHIF1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119233997-A | Tetrahedral antibodies | 生物分子控股有限责任公司 | 2024-12-31 | — | — | CN | claimed |
| EP-4463485-A2 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2024-11-20 | — | — | EP | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| WO-2023137387-A2 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| WO-2023137373-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| US-20230220116-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-13 | — | — | US | claimed |
| US-20230220115-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-13 | — | — | US | claimed |
| EP-4178615-A1 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2023-05-17 | — | — | EP | claimed |
| US-11225490-B2 | Prodrugs of secondary amine compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-01-18 | — | — | US | claimed |
| WO-2022011358-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2022-01-13 | — | — | WO | claimed |
| EP-1192129-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-04-03 | — | — | EP | claimed |
| EP-1169298-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-01-09 | — | — | EP | claimed |
| US-6302875-B1 | Catheters and related devices for forming passageways between blood vessels or other anatomical structures | TRANSVASCULAR, INC. | 2001-10-16 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| WO-2001012584-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2001-02-22 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061541-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220115-A1 | TETRAHEDRAL ANTIBODIES | FCGR3B, FCGR2A, FCGR1A | ADRA1A 4669/4885CYP2D6 4821/4885ADRA2A 4717/4885 |
| US-20230220116-A1 | TETRAHEDRAL ANTIBODIES | FCGR3B, FCGR2A, FCGR1A | ADRA1A 4669/4885CYP2D6 4821/4885ADRA2A 4717/4885 |
| US-11225490-B2 | Prodrugs of secondary amine compounds | HNMT, MAOB, UGT1A1 | ADRA1A 328/4885CYP2D6 10/4885ADRA2A 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.